Normal Outcome Following Administration of Gonadotropin-Releasing Hormone (GnRH) Agonist during Early Pregnancy

We observed an unusual case of a woman who had received a gonadotropinreleasing hormone (GnRH) agonist (GnRH‐a), leuprolide acetate, during the first trimester and early in the second trimester of pregnancy. Nevertheless, the pregnancy was uncomplicated and a healthy male infant (2,670 g) was born after spontaneous labor at the 38th week of gestation. The infant suffered no malformations or respiratory complication and he achieved normal growth. Although GnRH‐a is known to induce pregnancy loss, the drug does not appear to be teratogenic. Accordingly, a pregnancy that occurs during GnRH‐a therapy and progresses normally should not be terminated for fear of its teratogenic effects.